JP2020529863A5 - - Google Patents
Info
- Publication number
- JP2020529863A5 JP2020529863A5 JP2020520426A JP2020520426A JP2020529863A5 JP 2020529863 A5 JP2020529863 A5 JP 2020529863A5 JP 2020520426 A JP2020520426 A JP 2020520426A JP 2020520426 A JP2020520426 A JP 2020520426A JP 2020529863 A5 JP2020529863 A5 JP 2020529863A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- variable region
- chain variable
- Prior art date
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023015342A JP7464764B2 (ja) | 2017-06-25 | 2023-02-03 | 抗ｒｏｒ１抗体とその作製及び使用方法 |
Applications Claiming Priority (15)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762524554P | 2017-06-25 | 2017-06-25 | |
| US201762524557P | 2017-06-25 | 2017-06-25 | |
| US201762524558P | 2017-06-25 | 2017-06-25 | |
| US62/524,558 | 2017-06-25 | ||
| US62/524,554 | 2017-06-25 | ||
| US62/524,557 | 2017-06-25 | ||
| US201762545603P | 2017-08-15 | 2017-08-15 | |
| US62/545,603 | 2017-08-15 | ||
| US201762551032P | 2017-08-28 | 2017-08-28 | |
| US201762551065P | 2017-08-28 | 2017-08-28 | |
| US201762551035P | 2017-08-28 | 2017-08-28 | |
| US62/551,065 | 2017-08-28 | ||
| US62/551,035 | 2017-08-28 | ||
| US62/551,032 | 2017-08-28 | ||
| PCT/US2018/039152 WO2019005636A2 (en) | 2017-06-25 | 2018-06-22 | ANTI-ROR1 ANTIBODIES AND METHODS OF PREPARATION AND USE |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023015342A Division JP7464764B2 (ja) | 2017-06-25 | 2023-02-03 | 抗ｒｏｒ１抗体とその作製及び使用方法 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2020529863A JP2020529863A (ja) | 2020-10-15 |
| JP2020529863A5 true JP2020529863A5 (https=) | 2022-01-17 |
| JPWO2019005636A5 JPWO2019005636A5 (https=) | 2022-01-17 |
| JP7222987B2 JP7222987B2 (ja) | 2023-02-15 |
Family
ID=64742585
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020520426A Active JP7222987B2 (ja) | 2017-06-25 | 2018-06-22 | 抗ｒｏｒ１抗体とその作製及び使用方法 |
| JP2020520428A Active JP7323513B2 (ja) | 2017-06-25 | 2018-06-22 | 抗４－１ｂｂ抗体とその作製及び使用方法 |
| JP2023015342A Active JP7464764B2 (ja) | 2017-06-25 | 2023-02-03 | 抗ｒｏｒ１抗体とその作製及び使用方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020520428A Active JP7323513B2 (ja) | 2017-06-25 | 2018-06-22 | 抗４－１ｂｂ抗体とその作製及び使用方法 |
| JP2023015342A Active JP7464764B2 (ja) | 2017-06-25 | 2023-02-03 | 抗ｒｏｒ１抗体とその作製及び使用方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US11987635B2 (https=) |
| EP (2) | EP3645742B1 (https=) |
| JP (3) | JP7222987B2 (https=) |
| CN (7) | CN116789832A (https=) |
| WO (2) | WO2019005636A2 (https=) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201710838D0 (en) | 2017-07-05 | 2017-08-16 | Ucl Business Plc | Bispecific antibodies |
| GB201710836D0 (en) | 2017-07-05 | 2017-08-16 | Ucl Business Plc | ROR1 Car T-Cells |
| GB201710835D0 (en) | 2017-07-05 | 2017-08-16 | Ucl Business Plc | ROR1 Antibodies |
| WO2020018964A1 (en) | 2018-07-20 | 2020-01-23 | Fred Hutchinson Cancer Research Center | Compositions and methods for controlled expression of antigen-specific receptors |
| CN115485298A (zh) * | 2020-01-30 | 2022-12-16 | 英克特诺治疗公司 | 用于治疗癌症的egfr抑制剂和ror1抑制剂的组合 |
| AU2021225920A1 (en) * | 2020-02-28 | 2022-09-15 | Shanghai Henlius Biotech, Inc. | Anti-CD137 construct and use thereof |
| CN111499746B (zh) * | 2020-04-28 | 2020-11-24 | 优睿赛思(武汉)生物科技有限公司 | 一种针对人白介素-2的高亲和力兔单克隆抗体及其应用 |
| EP4188430A4 (en) * | 2020-07-28 | 2024-11-06 | The Board Of Regents Of The University Of Texas System | Monoclonal antibodies against lilrb1 for diagnostic and therapeutic use |
| TWI818308B (zh) * | 2020-09-03 | 2023-10-11 | 大陸商和鉑醫藥（上海）有限責任公司 | 標靶ｒｏｒ１的抗體或其抗原結合片段及製備方法和應用 |
| AU2022227686A1 (en) | 2021-02-25 | 2023-07-27 | Lyell Immunopharma, Inc. | Ror1 targeting chimeric antigen receptor |
| CN115433277A (zh) * | 2021-06-05 | 2022-12-06 | 苏州缔码生物科技有限公司 | 抗cd38兔重组单克隆抗体的制备及应用 |
| TW202320858A (zh) | 2021-07-19 | 2023-06-01 | 美商薩諾管理公司 | 免疫接合物及方法 |
| US11806405B1 (en) | 2021-07-19 | 2023-11-07 | Zeno Management, Inc. | Immunoconjugates and methods |
| JP2024540099A (ja) | 2021-10-28 | 2024-10-31 | ライエル・イミュノファーマ・インコーポレイテッド | Ｒｏｒ１結合タンパク質を発現する細胞を培養する方法 |
| CN116333139B (zh) * | 2021-12-22 | 2026-02-27 | 上海复旦张江生物医药股份有限公司 | 一种抗fda0128抗体、其制备方法和应用 |
| WO2024064952A1 (en) | 2022-09-23 | 2024-03-28 | Lyell Immunopharma, Inc. | Methods for culturing nr4a-deficient cells overexpressing c-jun |
| WO2024064958A1 (en) | 2022-09-23 | 2024-03-28 | Lyell Immunopharma, Inc. | Methods for culturing nr4a-deficient cells |
| WO2024077174A1 (en) | 2022-10-05 | 2024-04-11 | Lyell Immunopharma, Inc. | Methods for culturing nr4a-deficient cells |
| WO2024160721A1 (en) | 2023-01-30 | 2024-08-08 | Kymab Limited | Antibodies |
| CN118745226B (zh) * | 2023-06-07 | 2026-02-17 | 浙江博锐生物制药有限公司 | 抗ror1抗体及其应用 |
| CN117467004B (zh) * | 2023-10-09 | 2024-06-21 | 武汉爱博泰克生物科技有限公司 | 抗人钙网膜蛋白的兔单克隆抗体及其应用 |
| WO2025106600A2 (en) * | 2023-11-15 | 2025-05-22 | Systimmune, Inc. | Anti-dll3 antibody and method of making and using thereof |
| CN117624355B (zh) * | 2023-11-30 | 2024-05-14 | 无锡傲锐东源生物科技有限公司 | 一种抗人乙酰化tau274兔单克隆抗体及其应用 |
| CN117736330B (zh) * | 2024-01-24 | 2024-05-17 | 上海沙砾生物科技有限公司 | 肿瘤坏死因子超家族受体9的特异性抗原结合蛋白及其应用 |
| WO2025217398A1 (en) | 2024-04-10 | 2025-10-16 | Lyell Immunopharma, Inc. | Methods for culturing cells with improved culture medium |
| CN118930648B (zh) * | 2024-08-22 | 2025-02-28 | 武汉爱博泰克生物科技有限公司 | 抗人pax8蛋白的兔单克隆抗体、抗体偶联物及其应用 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| AU2002364935A1 (en) * | 2001-10-09 | 2003-06-23 | Mayo Foundation For Medical Education And Research | Enhancement of immune responses by 4-1bb-binding agents |
| AR046094A1 (es) * | 2003-10-10 | 2005-11-23 | Bristol Myers Squibb Co | Anticuerpos completamente humanos contra 4-1bb humano |
| US20080152655A1 (en) * | 2004-09-08 | 2008-06-26 | The Ohio State University Research Foundation | Combination Therapy With Anti-Ctla4 and Anti-4-1BB Antibodies |
| AU2015252014B2 (en) * | 2009-04-23 | 2017-03-02 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-human ror1 antibodies |
| PT2614082T (pt) * | 2010-09-09 | 2018-12-03 | Pfizer | Moléculas de ligação a 4-1bb |
| US9758586B2 (en) * | 2010-12-01 | 2017-09-12 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric rabbit/human ROR1 antibodies |
| GB201020995D0 (en) * | 2010-12-10 | 2011-01-26 | Bioinvent Int Ab | Biological materials and uses thereof |
| DK3252076T3 (da) * | 2011-01-14 | 2019-12-02 | Univ California | Diagnostisk anvendelse af antistoffer mod ror-1-protein |
| HRP20201595T1 (hr) * | 2011-11-28 | 2020-12-11 | Merck Patent Gmbh | Anti-pd-l1 protutijela i njihova uporaba |
| PL3489261T3 (pl) * | 2012-08-24 | 2021-08-16 | The Regents Of The University Of California | Przeciwciała i szczepionki do stosowania w leczeniu nowotworów z ekspresją ROR1 i w hamowaniu przerzutu |
| US9139649B2 (en) * | 2014-02-25 | 2015-09-22 | Immunomedics, Inc. | Humanized anti-CD22 antibody |
| SG11201704741PA (en) * | 2014-12-22 | 2017-07-28 | Systimmune Inc | Bispecific tetravalent antibodies and methods of makiing and using thereof |
| CN104817642B (zh) * | 2015-05-04 | 2018-03-27 | 北京百普赛斯生物科技有限公司 | 抗人ror1单克隆抗体及其制备方法与应用 |
| US20210008113A1 (en) * | 2018-03-27 | 2021-01-14 | Systimmune, Inc. | Methods of making and using guidance and navigation control proteins |
-
2018
- 2018-06-22 WO PCT/US2018/039152 patent/WO2019005636A2/en not_active Ceased
- 2018-06-22 EP EP18825285.2A patent/EP3645742B1/en active Active
- 2018-06-22 WO PCT/US2018/039155 patent/WO2019005638A2/en not_active Ceased
- 2018-06-22 CN CN202310929184.9A patent/CN116789832A/zh active Pending
- 2018-06-22 CN CN201880038385.7A patent/CN110799539B/zh active Active
- 2018-06-22 US US16/615,119 patent/US11987635B2/en active Active
- 2018-06-22 CN CN202310929014.0A patent/CN116769035A/zh active Pending
- 2018-06-22 CN CN202310854068.5A patent/CN116731180A/zh active Pending
- 2018-06-22 CN CN201880038332.5A patent/CN110869389B/zh active Active
- 2018-06-22 US US16/615,116 patent/US11518815B2/en active Active
- 2018-06-22 EP EP18824588.0A patent/EP3645741A4/en active Pending
- 2018-06-22 CN CN202310854150.8A patent/CN116925227A/zh active Pending
- 2018-06-22 JP JP2020520426A patent/JP7222987B2/ja active Active
- 2018-06-22 JP JP2020520428A patent/JP7323513B2/ja active Active
- 2018-06-22 CN CN202310854013.4A patent/CN116731179A/zh active Pending
-
2023
- 2023-02-03 JP JP2023015342A patent/JP7464764B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020529863A5 (https=) | ||
| JP2020529862A5 (https=) | ||
| JPWO2019005636A5 (https=) | ||
| JP2020531043A5 (https=) | ||
| JP7685095B2 (ja) | 多重特異性抗体とその作製及び使用方法 | |
| IL276830B2 (en) | Anti-claudin 18.2 antibodies and uses thereof | |
| JP2020530776A5 (https=) | ||
| JP2021515559A5 (https=) | ||
| JP7399852B2 (ja) | 多重特異性抗体とその作製及び使用方法 | |
| RU2008135132A (ru) | Антитела-антагонисты интерлейкина-17 (ил-17) для лечения рака | |
| RU2014101669A (ru) | Агенты, связывающие белки r-спондины (rspo), и способы их применения | |
| TW202537975A (zh) | 抗體－藥物結合物之製造方法 | |
| JP2020502271A5 (https=) | ||
| JP2020501531A5 (https=) | ||
| FI3218005T3 (fi) | Glykaanin kanssa vuorovaikutteisia yhdisteitä ja käyttömenetelmiä | |
| JPWO2019173692A5 (https=) | ||
| FI3452513T3 (fi) | Humanisoituja anti-il-1r3-vasta-aineita | |
| RU2016147206A (ru) | Полипептиды и полинуклеотиды и их применение для лечения иммунологических нарушений и рака | |
| RU2017114968A (ru) | Связывающие молекулы, а именно антитела, способные связываться с l1cam (cd171) | |
| JPWO2019005638A5 (https=) | ||
| JP2022526841A5 (https=) | ||
| JP2021501575A5 (https=) | ||
| JPWO2023288241A5 (https=) | ||
| JPWO2020237173A5 (https=) | ||
| JPWO2019005635A5 (https=) |